COVID-19: Mystery Company Eyes EU Approval For Dexamethasone Taw

The European Medicines Agency has started reviewing under its fast-track pathway an application to market Dexamethasone Taw as a treatment for hospitalized patients with COVID-19.

multiexposure background coronavirus COVID 19 infected blood sample in sample tube in hand of scientist in coronavirus research laboratory with DNA strain, coronavirus covid 19 vaccine research
Dexamethasone has shown promise as a treatment for hospitalized patients with COVID-19 • Source: Shutterstock

Dexamethasone could potentially soon be authorized for use in the EU for treating hospitalized adult patients with COVID-19, after the European Medicines Agency today said it had begun evaluating a marketing application for a product called Dexamethasone Taw for this purpose.

The application, submitted by the UK consultancy firm Taw Pharma on behalf of an unnamed drug company, is being reviewed...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet